Boehringer Ingelheim Announces Thursday July 16 the Start of a Phase 2 Clinical Trial Evaluating BI 3034701, a Gubra-Discovered First-in-Class Investigational Triple GLP-1/GIP/NPY2 Receptor Agonist Peptide in Patients With Obesity and Overweight: The Molecule Simultaneously Activates GLP-1 and GIP Receptors to Reduce Appetite and Regulate Metabolism, Plus the Neuropeptide Y2 (NPY2) Receptor to Modulate Central Hunger Signaling — Adding a Third Target Beyond the GLP-1/GIP Dual (Tirzepatide) and GLP-1/GIP/Glucagon Triple (Retatrutide) Approaches Already Dominating the Pipeline
Boehringer Ingelheim announced Thursday July 16, 2026 the start of a Phase 2 clinical trial evaluating BI 3034701, its investigational triple GLP-1/GIP/NPY2 receptor agonist peptide, in patients with obesity and overweight. BI 3034701 is a potential first-in-class triple agonist designed to activate three complementary biological pathways: GLP-1 and GIP receptors reduce appetite and regulate metabolism, and the neuropeptide Y2 (NPY2) receptor modulates central hunger signaling. Phase 1 studies previously showed a generally favorable safety and tolerability profile that supported advancing the program. BI 3034701 is based on Gubra-discovered technology and licensed to Boehringer Ingelheim, which is responsible for global clinical development and commercialization. The program adds a distinct third target to the emerging next-generation obesity landscape: Eli Lilly's retatrutide (GLP-1/GIP/glucagon triple agonist in TRIUMPH Phase 3), Novo Nordisk's UBT251 (GLP-1/GIP/glucagon triple in Phase 1/2a), and Boehringer's dual glucagon/GLP-1 survodutide (Phase 3, 16.6% weight loss in obesity). The NPY2 receptor target is novel to the class and could carry a distinct safety and tolerability profile alongside the incretin-plus-incretin backbone.